dopamine receptor antagonists (Buffalo/Chakra/Tikvah)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namedopamine receptor antagonists (Buffalo/Chakra/Tikvah)
Drug Alias NameCB-1 (Chakra)CB-030006CB-2CB-4CB-3
ClassificationSmall molecules
Mechanisms of ActionSerotonin 6 (5-HT6) receptor antagonistsDopamine D2 receptor antagonistsNorepinephrine reuptake inhibitors +[4] 
TargetsSerotonin 2c (5-HT2c) receptorSerotonin 6 (5-HT6) receptorNorepinephrine transporter +[4] 
Therapy Area/IndicationsSchizophreniaBipolar Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingapore
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity At Buffalo
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCerca Insights Sdn BhdTikvah TherapeuticsUniversity At Buffalo
Active IndicationsN/A
Inactive IndicationsSchizophreniaBipolar Disorder

Other Information

ATC CodeN/A
Related LinksN/A